poisar

Stocks · News reference

Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference

Jun 16, 2026, 1:18 PMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NXL
Source
benzinga
Observed
Jun 16, 2026, 1:18 PM
Checked
Jun 16, 2026, 1:25 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Aug 27, 2026, 11:30 AMSEC EDGAR

    8-K filing — Nexalin Technology, Inc. (NXL)

    Filed: 2026-08-27 AccNo: 0001829126-26-009387 Size: 241 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    Read original at edgar
    NXL